Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141
Conditions:   Solid Tumor;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma;   Esophageal Adenocarcinoma;   Pancreatic Cancer;   Biliary Tract Cancer;   Cholangiocarcinoma;   Metastatic Cancer
Interventions:   Biological: BNT141;   Drug: Nab-paclitaxel;   Drug: Gemcitabine
Sponsor:   BioNTech SE
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 16, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments